Erenumab for Preventive Treatment of Migraine: A Systematic Review and Meta-Analysis of Efficacy and Safety
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Erenumab for Preventive Treatment of Migraine: A Systematic Review and Meta-Analysis of Efficacy and Safety
Authors
Keywords
-
Journal
DRUGS
Volume 79, Issue 4, Pages 417-431
Publisher
Springer Nature
Online
2019-02-22
DOI
10.1007/s40265-019-01069-1
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- ARISE: A Phase 3 randomized trial of erenumab for episodic migraine
- (2018) David W Dodick et al. CEPHALALGIA
- Patent Foramen Ovale and Cryptogenic Stroke or Transient Ischemic Attack: To Close or Not to Close? A Systematic Review and Meta-Analysis
- (2018) Simona Lattanzi et al. CEREBROVASCULAR DISEASES
- Adjunctive Eslicarbazepine Acetate in Pediatric Patients with Focal Epilepsy: A Systematic Review and Meta-Analysis
- (2018) Simona Lattanzi et al. CNS DRUGS
- A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Erenumab on Exercise Time During a Treadmill Test in Patients With Stable Angina
- (2018) Christophe Depre et al. HEADACHE
- Endovascular treatment of symptomatic vertebral artery stenosis: A systematic review and meta-analysis
- (2018) Simona Lattanzi et al. JOURNAL OF THE NEUROLOGICAL SCIENCES
- Migraine-related disability, impact, and health-related quality of life among patients with episodic migraine receiving preventive treatment with erenumab
- (2018) Dawn C Buse et al. CEPHALALGIA
- Efficacy and Safety of Adjunctive Cannabidiol in Patients with Lennox–Gastaut Syndrome: A Systematic Review and Meta-Analysis
- (2018) Simona Lattanzi et al. CNS DRUGS
- The efficacy and safety of calcitonin gene-related peptide monoclonal antibody for episodic migraine: a meta-analysis
- (2018) Yuhan Zhu et al. NEUROLOGICAL SCIENCES
- CGRP Antibodies as Prophylaxis in Migraine
- (2018) Lars Edvinsson CELL
- Efficacy and Safety of Cannabidiol in Epilepsy: A Systematic Review and Meta-Analysis
- (2018) Simona Lattanzi et al. DRUGS
- Early onset of efficacy with erenumab in patients with episodic and chronic migraine
- (2018) Todd Schwedt et al. JOURNAL OF HEADACHE AND PAIN
- Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study
- (2018) Uwe Reuter et al. LANCET
- CGRP/CGRP Receptor Antibodies: Potential Adverse Effects Due to Blockade of Neovascularization?
- (2018) Masataka Majima et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- Psychometric Evaluation of a Novel Instrument Assessing the Impact of Migraine on Physical Functioning: The Migraine Physical Function Impact Diary
- (2017) Ariane K. Kawata et al. HEADACHE
- Efficacy and safety of perampanel in Parkinson’s disease. A systematic review with meta-analysis
- (2017) Simona Lattanzi et al. JOURNAL OF NEUROLOGY
- Oral and intravenous steroids for multiple sclerosis relapse: a systematic review and meta-analysis
- (2017) Simona Lattanzi et al. JOURNAL OF NEUROLOGY
- Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial
- (2017) Stewart Tepper et al. LANCET NEUROLOGY
- A Controlled Trial of Erenumab for Episodic Migraine
- (2017) Peter J. Goadsby et al. NEW ENGLAND JOURNAL OF MEDICINE
- Persistence and switching patterns of oral migraine prophylactic medications among patients with chronic migraine: A retrospective claims analysis
- (2016) Zsolt Hepp et al. CEPHALALGIA
- Safety and efficacy of AMG 334 for prevention of episodic migraine: a randomised, double-blind, placebo-controlled, phase 2 trial
- (2016) Hong Sun et al. LANCET NEUROLOGY
- Drug safety and tolerability in prophylactic migraine treatment
- (2015) László Vécsei et al. Expert Opinion On Drug Safety
- Adherence to oral migraine-preventive medications among patients with chronic migraine
- (2014) Zsolt Hepp et al. CEPHALALGIA
- Calcitonin Gene-Related Peptide: Physiology and Pathophysiology
- (2014) F. A. Russell et al. PHYSIOLOGICAL REVIEWS
- CGRP in the trigeminovascular system: a role for CGRP, adrenomedullin and amylin receptors?
- (2013) C S Walker et al. BRITISH JOURNAL OF PHARMACOLOGY
- Cost and Predictors of Lost Productive Time in Chronic Migraine and Episodic Migraine: Results from the American Migraine Prevalence and Prevention (AMPP) Study
- (2013) Daniel Serrano et al. VALUE IN HEALTH
- Targeting a family B GPCR/RAMP receptor complex: CGRP receptor antagonists and migraine
- (2012) Eric L Moore et al. BRITISH JOURNAL OF PHARMACOLOGY
- Cost of healthcare for patients with migraine in five European countries: results from the International Burden of Migraine Study (IBMS)
- (2012) L. M. Bloudek et al. JOURNAL OF HEADACHE AND PAIN
- Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010
- (2012) Theo Vos et al. LANCET
- Assessing and Managing All Aspects of Migraine: Migraine Attacks, Migraine-Related Functional Impairment, Common Comorbidities, and Quality of Life
- (2012) Dawn C. Buse et al. MAYO CLINIC PROCEEDINGS
- Cost of Health Care Among Patients With Chronic and Episodic Migraine in Canada and the USA: Results From the International Burden of Migraine Study (IBMS)
- (2011) Michael Stokes et al. HEADACHE
- The potent calcitonin gene-related peptide receptor antagonist, telcagepant, does not affect nitroglycerin-induced vasodilation in healthy men
- (2010) Bart J. Van der Schueren et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- CGRP and its receptors provide new insights into migraine pathophysiology
- (2010) Tony W. Ho et al. Nature Reviews Neurology
- Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
- (2009) David Moher et al. PLOS MEDICINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started